A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

This study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet chemotherapy compared with platinum-based doublet chemotherapy in treating subjects with locally advanced or metastatic non-squamous NSCLC who have not received previous systemic treatment and MET-positive. The target population of this study is subjects with histologically confirmed locally advanced or metastatic non-squamous NSCLC who have not received previous systemic anti-t

Trial Details

NCT ID
NCT06930794
Phase
PHASE3
Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Vebreltinib combined with platinum-based doublet chemotherapy.
  • platinum-based doublet chemotherapy.
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • male or female subjects ≥ 18 years of age at the time of signing ICF.
  • histologically or cytologically confirmed diagnosis of non-radical, locally advanced (Stage IIIB and IIIC) or metastatic (Stage IV) non-squamous ce…
  • Part 1 (introductory stage)Subjects with MET-positive (MET amplification or MET overexpression) tumors will be enrolled. MET amplification is defin…
  • Part 1 (Lead-in Period): Documented evidence confirms that the tumor tissue specimen tested negative for sensitive epidermal growth factor receptor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →